【摘要】 针对急性心肌梗死(AMI)并发泵衰竭患者药物治疗不佳的难点,使用国产新型钙增敏剂左西孟旦治疗,观察药物治疗的临床有效率、心衰恶化或死亡率、超声心动图(UCG)左室射血分数(LVEF)及氨基末端脑钠肽前体(NT-ProBNP)、高敏C-反应蛋白(hs-CRP)的变化,结果表明国产左西孟旦治疗急性心肌梗死合并泵衰竭疗效确切,安全性及患者耐受性良好.更多还原

【Abstract】 Due to the poor efficacy of routine drug therapy in patients with pump failure due to an acute myocardial infarction,a domestic new calcium sensitizer levosimendan treatment is researched in this paper. The changes in the clinical effective rate,ultrasonic cardiogram( UCG) and amino terminal brain natriuretic peptide precursor( NT-ProBNP),allergic C-reactive protein( hs-CRP) are then observed. The results show that domestic levosimendan has definite therapeutic effect on acute myocardial infarction with pump failure,which is safe and well tolerated in patients.更多还原